Dexmedetomidine protects the heart against ischemia-reperfusion injury by an endothelial eNOS/NO dependent mechanism by Riquelme, JA et al.
 1 
Biochemical Pharmacology-August 17, 2015  
 
 
Dexmedetomidine protects the heart against ischemia-
reperfusion injury by an eNOS/NO/PKG dependent mechanism  
 
Jaime A Riquelme1, Francisco Westermeier1, Andrew R Hall2, José Miguel 
Vicencio2, Zully Pedrozo1,3, Mauricio Ibacache4, Bárbara Fuenzalida5 Luis 
Sobrevía5,6, Sean M Davidson2, Derek M Yellon2, Gina Sánchez3* and Sergio 
Lavandero1,3,7*. 
 
1 Advanced Center for Chronic Disease (ACCDiS), Facultad de Ciencias 
Químicas y Farmacéuticas & Facultad de Medicina, Universidad de Chile, 
Santiago, Chile. 
2 The Hatter Cardiovascular Institute, University College London, London, United 
Kingdom. 
3 Instituto de Ciencias Biomédicas (ICBM), Facultad de Medicina, Universidad de 
Chile, Santiago, Chile. 
4 División de Anestesiología. Facultad Medicina, Pontificia Universidad Católica 
de Chile, Santiago, Chile. 
5 Cellular and Molecular Physiology Laboratory (CMPL), Division of Obstetrics 
and Gynecology, School of Medicine, Faculty of Medicine, Pontificia 
Universidad Católica de Chile, Santiago, Chile 
6 University of Queensland Centre for Clinical Research (UQCCR), Faculty of 
Medicine and Biomedical Sciences, University of Queensland, Herston,  
Queensland, Australia 
7 Department of Internal Medicine (Cardiology Division), University of Texas 
Southwestern Medical Center, Dallas, Texas, USA. 
 
 
 
 
 
*Corresponding authors at: Facultad de Medicina, Universidad de Chile. 
Independencia 1027, Santiago 8380492 (G Sanchez) or Advanced Center for 
Chronic Diseases (ACCDiS) Facultad Ciencias Químicas y Farmacéuticas, 
Universidad de Chile, Olivos 1007, Santiago 8380492, Chile (S Lavandero). 
E-mail address: gisanchez@med.uchile.cl (G Sánchez) or slavander@uchile.cl  
(S Lavandero) 
 
 2 
Abstract 
 
The alpha2-adrenergic receptor agonist Dexmedetomidine (Dex) is a sedative 
medication used by intensive care units and anesthesiologists. Previous reports 
have shown that Dex protects the heart against ischemia-reperfusion (IR) and 
can also act as a preconditioning mimetic. However, the 
biochemical/pharmacological mechanisms involved in Dex-dependent cardiac 
preconditioning, and whether this action occurs directly or indirectly on 
cardiomyocytes, still remain unclear. The endothelial nitric oxide synthase 
(eNOS)/nitric oxide (NO)/cyclic GMP dependent kinase (PKG) signaling pathway 
and endothelial cells are known to play key roles in cardioprotection against IR 
injury. Therefore, the aims of this work were to evaluate whether the 
eNOS/NO/PKG pathway mediates the pharmacological cardiac effect of Dex, 
and whether endothelial cells are required in this cardioprotective action. 
Isolated adult rat hearts were treated with Dex (10 nM) for 25 min and the 
dimerization of eNOS and production of NO measured. , Hearts were then 
subjected to 30 min of global ischemia and 120 min of reperfusion and the role of 
the eNOS/NO/PKG pathway was evaluated. Dexmedetomidine promoted the 
activation of eNOS and production of NO. Furthermore, Dexmedetomidine 
reduced the infarct size and improved the left ventricle function recovery, but this 
effect was reversed when Dexmedetomidine was co-administered with inhibitors 
of the eNOS/NO/PKG pathway. In addition, Dexmedetomidine was unable to 
reduce cell death in isolated adult rat cardiomyocytes subjected to simulated IR 
(sIR). However, cell death of cardiomyocytes was attenuated by co-culturing 
them with endothelial cells that were pre-treaed with Dex. In summary, our 
results show that Dexmedetomidine triggers cardiac protection by activating the 
eNOS/NO/PKG signaling pathway. This pharmacological effect of 
Dexmedetomidine requires its interaction with the endothelium. 
 
Keywords:  Dexmedetomidine, α2-adrenergic receptor, heart, 
endothelium, preconditioning, ischemia-reperfusion.  
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Chemical compounds: Dexmedetomidine, hydrochloride (PubChem CID: 
6918081), L-NAME hydrochloride (PubChem CID: 135193), PTIO (PubChem 
CID: 2733513), KT5823 (PubChem CID: 108152). 
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1. Introduction 
 
Dexmedetomidine (Dex) is a lipophilic, highly selective and specific agonist 
of alpha2-adrenergic receptors [1, 2]. In clinical settings, Dex is used for 
perioperative and intensive care sedation due to its analgesic and anxiolytic 
effects [3]. The specific stimulation of alpha2-adrenergic receptors (subtypes 2A, 
2B, 2C) in the nervous system determines the analgosedative effects observed 
during Dex administration  [4, 5]. Dex also demonstrates a biphasic blood 
pressure response, with an initial increase attributable to vasoconstriction after 
activation of alpha2/betaadrenergic receptors in the vascular smooth muscle, 
followed by a decrease in blood pressure, after activation of alpha2A-adrenergic 
receptors in the central nervous system [6-8]. Furthermore, stimulation of 
postsynaptic alpha2-adrenergic receptors on endothelial cells produces 
vasodilatation [9]. The drug also reduces the release of stress hormones and 
catecholamines [8]. The modulation of the sympathetic nervous system 
theoretically maintains the balance in the input/demand relationship of myocardial 
oxygen. Dex is known to be protective in multiple organs and types of ischemia-
reperfusion (IR) injury [10]. The mechanism by which it protects may be organ-
specifc. The biochemical and pharmacological mechanisms reported to be 
involved in organ protection include: a) modulation of cell death by apoptosis 
[11]; b) activation of cell survival kinases [12, 13]; and, c) modulation of the 
inflammatory response and oxidative stress [14]. Few studies have addressed 
the pharmacological mechanism involved in Dex-dependent cardioprotection [15, 
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16]. Given the biphasic vascular effects of vasoconstriction and vasodilatation of 
the drug at coronary vessels, it was first proposed that Dex could mimic the effect 
of ischemic preconditioning [17]. Accordingly, previous work from our group 
showed that the cardioprotective effects of Dex are mediated by the activation of 
the RISK pathway after α2-adrenergic cardiac receptor stimulation [15]. 
Previous findings support the hypothesis that paracrine factors may also 
contribute to cardiomyocyte protection against IR injury. The coronary 
endothelium regulates coronary perfusion and cardiac function by producing 
vasoactive substances [18-20]. In the heart, nitric oxide (NO) is physiologically 
generated by endothelial nitric oxide synthase (eNOS) and neuronal endothelial 
nitric oxide synthase (nNOS), but the inducible nitric oxide synthase (iNOS) is an 
important source of NO under pathological conditions [21]. Available evidence 
suggests that eNOS-derived NO is a critical signaling molecule in different 
pharmacological cardioprotective strategies [22, 23]. We showed previously that 
Dex induces cardioprotection and activates eNOS in cardiac tissue [15]. 
However, the biochemical and pharmacological mechanisms involved in the 
potential production of endothelial NO induced by Dex and its role in 
cardiomyocyte protection are still not well defined. In order to study the 
downstream signaling involved in Dex’s protective effect, we evaluated the role of 
the eNOS/NO/PKG pathway and the participation of the endothelium in Dex 
preconditioning. 
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2. Materials and Methods 
 
2.1. Materials 
 
Antibodies against GAPDH, L-NG-nitroarginine methyl ester (L-NAME), 
2phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl 3-oxide (PTIO), (9S,10R,12R)-
2,3,9,10,11,12-hexahydro-10-methoxy-2,9-dimethyl-1-oxo-,12epoxy 1Hdiindolo 
[1,2,3-fg:3',2',1'-kl] pyrrolo[3,4-i] [1,6] benzodiazocine-10-carboxylic acid, methyl 
ester (KT5823), triphenyltetrazolium chloride, laminin, M-199 and insulin were 
obtained from Sigma-Aldrich (St Louis, MO). Dexmedetomidine.HCl was 
acquired from Hospira, Chile. Antibody against eNOS was purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA). Nitric oxide assay kit colorimetric was 
purchased from Abcam (Cambridge, MA). 
 
2.2. Animals 
 
The present study conforms to the Guide for the Care and Use of 
Laboratory Animals published by the U.S. National Institutes of Health 
(8th Edition, 2011) and was approved by our Institutional Ethics Review 
Committee. Rats were obtained from the Animal Breeding Facility of the Faculty 
of Chemical and Pharmaceutical Sciences, University of Chile. 
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2.3. Ex vivo isolated rat hearts 
 
Langendorff experiments were performed as previously described [24]. 
Adult male Sprague-Dawley rats (250-350 g) were anesthetized with sodium 
pentobarbital (80 mg/kg IP) and heparin 100 U/kg was administered. The hearts 
were rapidly excised and retrogradely perfused with Krebs Henseleit buffer via 
the aorta, containing (in mM): NaCl (128.3), KCl (4.7), CaCl2 (1.35), NaHCO3 
(20.2), NaH2PO4 (0.4), MgSO4 (1.1), glucose (11.1), pH 7.4 at 37 °C. Left 
ventricle (LV) functional data were obtained inserting a latex balloon in the 
ventricle and connected to a pressure transducer (Bridge Amp ML221 AD 
Instruments, Australia). The hearts were stabilized for 20 min and then subjected 
to 30 min of global ischemia and 120 min of reperfusion. 
 
2.4. Experimental protocols for ex vivo studies 
 
To evaluate if Dex could activate eNOS and generate NO, and to test if the 
eNOS/NO/PKG pathway mediates the preconditioning effect of the drug, rats 
were randomly assigned to different experimental groups. Treatments were 
administered between the end of the stabilization period and before global IR: 
Control group: 30 min of Krebs Henseleit buffer. Dex group: 25 min of Dex (10 
nM), followed by 5 min washout with Krebs Henseleit buffer. Dex was co-
administered with or without L-NAME (100 nM), PTIO (100 nM) or KT5823 
(1 µM) (Fig. 1). 
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2.5. Determination of infarct size 
 
The infarct size was measured through the triphenyltetrazolium chloride 
(TTC) technique as described previously [25]. At the end of reperfusion, the 
hearts were perfused with TTC 1% and frozen at -20 °C for 1 h. Then, hearts 
were cut into six slices and stored with formaldehyde 10% for 48 h before 
measuring the infarct area using the software imageJ. 
 
2.6. Evaluation of LV function 
 
The left ventricle developed pressure (LVDP), left ventricle end diastolic 
pressure (LVEDP) and the maximal positive and negative peak of ﬁrst derivative 
of LV pressure (+dP/dtmax, −dP/dtmin) were measured during the whole 
experiment on a computer using using PowerLab (ML866 ADInstruments, 
Australia) as described before [15]. 
 
2.7. Nitrite assay 
 
To measure nitrites, samples of the heart effluents from Control and Dex 
groups were collected during the administration period of the drug (0, 5, 10, and 
20 min). A sample after the 5 min washout with Krebs Henseleit was also 
collected. The quantification of nitrites was determined by the Griess reaction, 
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using the nitric oxide assay colorimetric kit ab65328 (Abcam), according to the 
manufacturer’s instructions. 
 
2.8. Whole heart homogenates 
 
 After the 5 min washout of Control and Dex groups, the ventricles were 
frozen using liquid N2 and the tissue was homogenized in cold buffer, containing 
(in mM): MOPS-Tris pH 7.0 (20), sucrose (300), EDTA (2), EGTA (2) Na3V04 
(10), NaF (80), Na4P2O7 (20), NP-40 1%, SDS 1%, and protease inhibitors 
leupeptin (2 μg/mL) and pepstatin (1 μg/mL), final pH 7.4. Samples were 
homogenized using a glass tissue grinder and centrifuged at 1000 x g for 20 min 
at 4 °C. Aliquots were frozen and stored at -80 °C for Western blot analysis. The 
protein concentration was determined by the Hartree method [26]. 
 
2.9. Western blot and eNOS dimer determination 
 
The assessment of eNOS dimers was performed as previously described 
[27]. Samples were run on low temperature (LT) SDS-PAGE. Whole heart 
homogenates were loaded on 8% SDS-gel, pre-equilibrated at 4 °C and the 
electrophoresis tank was maintained in ice to keep the gel below 10 °C. After 
LTSDS-PAGE, proteins were transferred to polyvinylidene difluoride membranes, 
and blocked with BSA 5%. Primary antibodies were used against eNOS (1:1000) 
and GAPDH (1:20000). The bands were quantified by densitometry using the 
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software imageJ. 
 
2.10. Adult rat cardiomyocyte isolation 
 
Adult male Sprague-Dawley rats were anesthetized with sodium 
pentobarbital (80 mg/kg IP), and the hearts were rapidly excised and perfused 
with collagenase II through the aorta. The cardiomyocytes were isolated as 
previously described [28] and plated on laminin (15 µg/mL) coated wells. The 
cells were maintained with M199 (Sigma) supplemented with 10% fetal calf 
serum and 1% penicillin-streptomycin and were allowed to attach for 18-24 h in a 
standard incubator at 37 °C with 95% O2 and 5% CO2. 
 
2.11. Endothelial cells and co-culture experiments 
 
HUVEC cells were maintained with EGM-2 BulletKit (Lonza Inc, Allendale, 
NJ) and were used between passage 3 and 9. For co-culture experiments, 
HUVEC cells were seeded into 6 well plate transwell inserts with 4 µm pores, 
according to the manufacturer’s instructions (Millipore). Cells were allowed to 
attach for 18-24 h. Next, HUVEC cells were stimulated with or without Dex (10 
nM) for 5 min and then co-cultured on plates with adult rat cardiomyocytes for 15 
min. Then, the transwells were removed and the primary cardiomyocytes were 
subjected to simulated ischemia/reperfusion. 
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2.12. Simulated ischemia-reperfusion  (sIR) 
 
Adult rat cardiomyocytes were subjected to in vitro sIR using a standard 
method [29]. The M-199 medium was replaced with a buffer that simulates the 
alterations during ischemia, containing (in mM): NaCl (128), NaHCO3 (2.2), KCl 
(14.8), MgSO4 (1.2), K2HPO4 (1.2), CaCl2 (1), Na-lactate (10) (pH 6.4). The cells 
were placed in a hypoxic chamber containing 95% N2 and 5 % CO2 for 3 h. Then, 
cardiomyocytes were reperfused with normoxic buffer for 1 h and placed in a 
standard incubator at 37 °C with 95% O2 and 5% CO2. Control cardiomyocytes 
were incubated with normoxic buffer, containing (in mM): NaCl (118), NaHCO3 
(22), KCl (2.6), MgSO4 (1.2), K2HPO4 (1.2), CaCl2 (1), glucose (10) (pH 7.4). 
 
2.13. mPTP opening assessment 
 
Mitochondrial permeability transition pore (mPTP) opening experiments were 
performed as previously described [30]. Adult rat cardiomyocytes were incubated 
with (3 µM) tetramethylrhodamine (TMRM) (a lipophilic cation that localizes to the 
mitochondria) for 20 min. TMRM was prepared in methanol, before being diluted 
into Tyrode’s buffer, containing (in mM): NaCl (137), KCl (5.4), MgCl2 (0.4), CaCl2 
(1), glucose (10), Hepes (10). Next, cells were treated with or without Dex (10 
nM) for 5 min. Laser illumination of the fluorophore using a confocal microscope 
with a 543 nm laser induces mitochondrial oxidative stress, and mPTP opening. 
The mPTP opening is associated with a release of the TMRM red dye from the 
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mitochondria to the cytosol, where the TMRM fluorescence is dequenched, 
resulting in an increase in cellular fluorescence. Pore opening was measured as 
the “half-time to maximal intensity” (sec). 
 
2.14. Cell death evaluation 
 
Adult rat cardiomyocytes subjected to sIR were stained with propidium 
iodide (PI) and the percentage of PI positive cells was assessed using a 
fluorescence microscope as previously described [29]. 
 
2.15. Statistical analysis 
 
Results are shown as representative images or as mean ± SEM of at least 
three independent experiments. Data was analyzed by t test, one or two-way 
ANOVA with either Bonferroni or Tukey’s post-test. Differences were considered 
significant at P<0.05. 
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3. Results 
 
3.1. Dex activates eNOS and promotes the generation of NO in isolated adult rat 
hearts 
 
To study the role of the eNOS-NO pathway in the cardiac preconditioning 
effect of Dex, we first evaluated whether Dex could activate eNOS and stimulate 
the production of NO in isolated adult rat hearts. Treatment with 10 nM Dex 
increased the generation of nitrites, a stable marker for NO [31], after 5, 10 and 
20 min of administration (Fig. 2A), and the increase was also maintained after 5 
min washout (Fig. 2B). To confirm our results, the dimerization of eNOS (the 
active form of the enzyme [32, 33]), was evaluated by Western blot analyses 
using LT-SDS-PAGE. Fig. 2C shows that perfusion of hearts with Dex (10 nM) 
increases the formation of eNOS dimer compared to the control. Thus, the results 
show that the preconditioning effect of Dex promotes the activation of eNOS and 
generation of NO in the heart. 
 
3.2. Dex attenuates IR injury through the eNOS-NO-PKG pathway in isolated 
adult rat hearts 
 
To assess if the eNOS/NO pathway plays a role in the cardioprotective 
effect of Dex, isolated adult rat hearts were preconditioned by perfusion with Dex 
(10 nM) for 25 min, before they being subjected to 30 min of global ischemia and 
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120 min of reperfusion. Dex reduced the infarct size (16 ±10%) compared to 
untreated hearts (42 ± 12%, P<0.05, N=5). This protection was eliminated when 
Dex was co-administered with the NOS inhibitor L-NAME (100 nM) or the NO 
scavenger PTIO (100 nM), (infarct sizes 42 ± 7% and 48 ± 13%, respectively, 
N=4, n.s. with respect to untreated hearts) (Fig. 3). In order to further explore the 
pathway downstream of NOS in Dex preconditioning, we evaluated the role of 
PKG. To test this, Dex (10 nM) was co-administered with the PKG inhibitor 
KT5823 (1 µM) and the protection was also abrogated (44 ± 16, N=4, n.s. with 
respect to untreated hearts) (Fig. 3). 
 
3.3. Dex improves LV function recovery through the eNOS/NO/PKG pathway in 
isolated adult rat hearts 
 
To confirm our results, LV function was measured. The results show that 
Dex (10 nM) improves the recovery of LVDP, LVEDP, +dP/dtmax, and -dP/dtmin 
at the end of reperfusion (Fig 4. A-D), whereas the co-administration of Dex with 
the eNOS-NO-PKG inhibitors prevents the recovery of LVDP, LVEDP, and 
+dP/dtmax (Fig 4A-C). Taken together, these results suggest that Dex protects 
against global I/R injury through the eNOS/NO/PKG pathway. 
 
3.4. Dex does not protect adult rat cardiomyocytes subjected to sIR 
 
 15 
To investigate whether Dex triggers protective responses directly on 
isolated cardiomyocytes, we first assessed if the drug was able to delay the 
formation of the mitochondrial permeability transition pore (mPTP) , a key factor 
for the onset of necrosis or apoptosis in IR [34-36]. To do this, adult rat 
cardiomyocytes were loaded with TMRM (3 µM) for 20 min and then treated them 
with or without Dex (10 nM) for 5 min. mPTP opening was measured by confocal 
microscopy. Dex was unable to delay the mPTP opening compared to the 
untreated control (Fig. 5A). Next, we tested the effect of Dex on cell death. To 
evaluate this, adult rat cardiomyocytes were subjected to 3 h of simulated 
ischemia and 1 h reperfusion and then stained with the vital dye propidium iodide 
(PI); we determined the percentage of PI+ cells using fluorescence microscopy. 
Insulin (10 nM) was used as a positive control for protection in this model. Our 
results show that sIR generated 63 ± 8% of cell death compared to normoxic 
conditions (18.7 ± 0.3%) and Dex did not protect against cell death generated by 
sIR (65 ± 8%, n.s. vs sIR, N= ?) (Fig. 5B). These results suggest that the 
cardioprotective actions of Dex on the heart are not via a direct effect on 
cardiomyocytes. 
 
3.5. Dex requires the endothelium to protect the cardiomyocyte against I/R injury 
 
We hypothesized that the presence of endothelial cells was necessary for 
Dex to exert its protective effect on cardiomyocytes. To this end, adult rat 
cardiomyocytes were co-cultured with HUVEC cells for 15 min in the presence or 
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absence of Dex, before removing the? cardiomyocytes and subjecting them to 
sIR. The results show that co-culture of cardiomyocytes with untreated 
endothelial cells was not protective (64 ± 10%), but when HUVEC cells were pre-
treated for 5 min with Dex (10  nM) prior to co-culture, the cell death of 
cardiomyocytes was reduced to 39 ± 6 % (Fig. 6). These indicate that Dex 
requires the presence of the endothelium to protect the myocardium against IR 
injury. 
 
4. Discussion 
 
This work shows that Dex activates eNOS and generates NO. In addition, 
we show for the first time that the cardiac preconditioning-mimicking effect of Dex 
is lost when the eNOS/NO/PKG pathway is inhibited. Moreover, we showed that 
Dex requires the endothelium to reduce cardiomyocyte death. Taken together, 
these novel findings suggest that Dex protects the myocardium through an 
eNOS/NO/PKG-dependent mechanism, and that cardiomyocyte protection of 
Dex is achieved indirectly via endothelial cells. 
Dex is known to be protective against IR in various organs including the 
kidneys, lung, brain and liver [14, 37-39]. The cardiac preconditioning effect of 
Dex has also been extensively demonstrated [15-17,40,41]. However, the exact 
biochemical mechanisms by which Dex attenuates IR injury are still being 
elucidated. Dex can protect against renal, lung and brain I/R through the 
regulation of the JAK/STAT, TLR4/MyD88/MAPK and RISK pathways, 
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respectively [14, 38, 42]. Regarding the heart, Okada et al described that Dex 
protected the myocardium against global IR. They discuss that vasoconstriction 
elicited by Dex may be triggering ischemic preconditioning [17]. Furthermore our 
previous studies have shown that Dex activated the RISK pathway in the 
myocardium [15]. This pathway has been shown by Yellon’s group to be central 
to the myocardial protection both as a consequence of preconditioning and 
against ischaemia-reperfusion injury (ref). 
In order to further study the downstream signaling involved in the Dex 
protective effect, we studied the role of the eNOS-NO signaling pathway. Our 
results show that Dex activated eNOS and generated NO, which is in agreement 
with our previous work showing that the drug promoted the phosphorylation of 
eNOS in the whole heart [15] and other studies that show that Dex can stimulate 
the production of NO in HUVEC cells [9, 43]. Despite this background, there are 
no studies showing that the preconditioning effect of Dex depends on this 
pathway. Our study shows that Dex cannot protect the heart when eNOS and NO 
are inhibited. 
The understanding of the pharmacological mechanism of Dex is essential to 
ensure its safe use. Dex is an alpha2-adrenergic receptor agonist used as a 
sedative in anesthesia [44]. Nevertheless, its cardioprotective effects still  remain 
to be fully elucidated. In this context, Dex has shown detrimental effects in the 
myocardium when used as a post-conditioning rather than a pre-conditioning 
agent [45]. This observation lead Cai et al to hypothesize that the protective 
effect of Dex depend on timing [10]. Our study may support this idea, since NO is 
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known to be cardioprotective against IR injury [46, 47]. However, when NO 
bioavailability increases during pro-oxidative conditions, such as reperfusion, it 
can react with superoxide and generate peroxynitrite, which is toxic to the 
myocardium [48-51]. Even though exploring this hypothesis is beyond the scope 
of this work, it may suggest that Dex should be administered as a preconditioning 
agent during the perioperative period rather than once the myocardial infarction 
has been developed. 
NO can potentially protect against IR injury through both PKG-independent 
and PKG-dependent mechanisms [51, 54], however, we found that PKG is 
necessary for protection by Dex. In the PKG-dependent pathway, NO activates 
soluble guanylate cyclase (sGC), which increases cyclic GMP to activate PKG. 
Interestingly, the cardioprotective effects of sGC activation have been shown to 
require PKG in cardiomyocytes [Methner et al Basic Res Cardiol. 2013 
Mar;108(2):337]. This supports our hypothesis that Dex stimulates production of 
NO in the endothelium, which then diffuses into cardiomyocytes to activate PKG 
downstream of sGC. 
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PKG has previously been shown to be cardioprotective in IR [52, 53]. The 
PKG pathway is known to cause vasodilatation [55], which could potentially 
improve reperfusion of the ischemic tissues. Interestingly, Okada et al found that 
the coronary flow in isolated rats hearts actually decreased during perfusion with 
Dex, although it returned to control values soon after the return to normal 
perfusate and was the same as control values during reperfusion [17]. 
Alternatively, PKG may protect through mechanisms independent of 
vasodilatation. For example, evidence shows that PKG can protect cells from IR 
injury by activating signaling cascades that delay mPTP opening [56-58]. 
Our previous study showed that the alpha2?–adrenergic receptors are 
expressed in the endothelium, but cardiomyocytes also express subtypes 2A and 
2C [ref]. Thus, we initially hypothesized that Dex could directly exert its 
preconditioning effect on the cardiomyocyte. Interestingly, our results suggested 
that Dex requires the presence of the endothelium to reduce cardiomyocyte 
death triggered by IR. In this context, cardiomyocytes represent roughly 75% of 
heart volume, but they are estimated to be less than 40% of the total number of 
cardiac cells [19, 59]. Cardiomyocytes are outnumbered by endothelial cells (3:1) 
and the distance from the capillary endothelium and the closest cardiomyocyte is 
1 μm [19]. This generates an ideal context for the interaction between these two 
cell types. Furthermore, the endothelium is required for protection against IR 
injury [23]. Moreover, the presence of endothelial cells is necessary for isoflurane 
to protect cardiomyocytes subjected to IR [22]. Thus, our findings agree with the 
concept that the endothelium is important to achieve pharmacological protection 
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against IR and that conditioning strategies should aim for the whole heart rather 
than the cardiomyocytes [59]. 
In conclusion, our results suggest that the eNOS/NO/PKG pathway 
mediates the pharmacological cardioprotective effect of Dex and that this 
protection requires the presence of a functioning endothelium. 
 
Funding 
 
This work was supported by FONDECYT (3140532 to F.W., 1130407 to 
G.S., 1153077 to L.S, 1150887 to Z.P.), CONICYT (FONDAP 15130011 to S.L.). 
We thank CONICYT-Chile for the Doctoral fellowship to J.R. 
 
Conflicts of interests 
None. 
 
Acknowledgments 
We thank G. Arce, R. Durán, F. Albornoz, G. Latorre, and L. Montecinos for 
their excellent technical assistance.  
 21 
References 
[1]  Virtanen R, Savola JM, Saano V, Nyman L. Characterization of the 
selectivity, specificity and potency of medetomidine as an alpha 2-
adrenoceptor agonist. European journal of pharmacology. 1988;150:9-14. 
[2]  Masuki S, Dinenno FA, Joyner MJ, Eisenach JH. Selective alpha2-
adrenergic properties of dexmedetomidine over clonidine in the human 
forearm. Journal of applied physiology. 2005;99:587-92. 
[3] Bhana N, Goa KL, McClellan KJ. Dexmedetomidine. Drugs. 2000;59:263-8; 
discussion 9-70. 
[4] Bylund DB. Heterogeneity of alpha-2 adrenergic receptors. Pharmacology, 
biochemistry, and behavior. 1985;22:835-43. 
[5] Bylund DB, Regan JW, Faber JE, Hieble JP, Triggle CR, Ruffolo RR, Jr. 
Vascular alpha-adrenoceptors: from the gene to the human. Canadian 
journal of physiology and pharmacology. 1995;73:533-43. 
[6] Belleville JP, Ward DS, Bloor BC, Maze M. Effects of intravenous 
dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate. 
Anesthesiology. 1992;77:1125-33. 
[7] Hamasaki J, Tsuneyoshi I, Katai R, Hidaka T, Boyle WA, Kanmura Y. Dual 
alpha(2)-adrenergic agonist and alpha(1)-adrenergic antagonist actions of 
dexmedetomidine on human isolated endothelium-denuded gastroepiploic 
arteries. Anesthesia and analgesia. 2002;94:1434-40, table of contents. 
[8] Snapir A, Posti J, Kentala E, Koskenvuo J, Sundell J, Tuunanen H, et al. 
Effects of low and high plasma concentrations of dexmedetomidine on 
myocardial perfusion and cardiac function in healthy male subjects. 
Anesthesiology. 2006;105:902-10; quiz 1069-70. 
[9] Joshi MS, Ferguson TB, Jr., Johnson FK, Johnson RA, Parthasarathy S, 
Lancaster JR, Jr. Receptor-mediated activation of nitric oxide synthesis by 
arginine in endothelial cells. Proceedings of the National Academy of 
Sciences of the United States of America. 2007;104:9982-7. 
[10] Cai Y, Xu H, Yan J, Zhang L, Lu Y. Molecular targets and mechanism of 
action of dexmedetomidine in treatment of ischemia/reperfusion injury. 
Molecular medicine reports. 2014;9:1542-50. 
[11] Engelhard K, Werner C, Eberspacher E, Bachl M, Blobner M, Hildt E, et al. 
The effect of the alpha 2-agonist dexmedetomidine and the N-methyl-D-
aspartate antagonist S(+)-ketamine on the expression of apoptosis-
regulating proteins after incomplete cerebral ischemia and reperfusion in 
rats. Anesthesia and analgesia. 2003;96:524-31, 
[12] Dahmani S, Paris A, Jannier V, Hein L, Rouelle D, Scholz J, et al. 
Dexmedetomidine increases hippocampal phosphorylated extracellular 
signal-regulated protein kinase 1 and 2 content by an alpha 2-adrenoceptor-
independent mechanism: evidence for the involvement of imidazoline I1 
receptors. Anesthesiology. 2008;108:457-66. 
[13] Eser O, Fidan H, Sahin O, Cosar M, Yaman M, Mollaoglu H, et al. The 
influence of dexmedetomidine on ischemic rat hippocampus. Brain 
research. 2008;1218:250-6. 
 22 
[14] Zhu YM, Wang CC, Chen L, Qian LB, Ma LL, Yu J, et al. Both PI3K/Akt and 
ERK1/2 pathways participate in the protection by dexmedetomidine against 
transient focal cerebral ischemia/reperfusion injury in rats. Brain research. 
2013;1494:1-8. 
[15] Ibacache M, Sanchez G, Pedrozo Z, Galvez F, Humeres C, Echevarria G, et 
al. Dexmedetomidine preconditioning activates pro-survival kinases and 
attenuates regional ischemia/reperfusion injury in rat heart. Biochimica et 
biophysica acta. 2012;1822:537-45. 
[16] Jiang C, Xia M, Wang M, Chen S. [Dexmedetomidine preconditioning 
protects isolated rat hearts against ischemia/reperfusion injuries and its 
mechanism]. Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang 
University Medical sciences. 2013;42:326-30. 
[17] Okada H, Kurita T, Mochizuki T, Morita K, Sato S. The cardioprotective effect 
of dexmedetomidine on global ischaemia in isolated rat hearts. 
Resuscitation. 2007;74:538-45. 
[18] Brutsaert DL, Fransen P, Andries LJ, De Keulenaer GW, Sys SU. Cardiac 
endothelium and myocardial function. Cardiovascular research. 
1998;38:281-90. 
[19] Brutsaert DL. Cardiac endothelial-myocardial signaling: its role in cardiac 
growth, contractile performance, and rhythmicity. Physiological reviews. 
2003;83:59-115. 
[20] Hsieh PC, Davis ME, Lisowski LK, Lee RT. Endothelial-cardiomyocyte 
interactions in cardiac development and repair. Annual review of 
physiology. 2006;68:51-66. 
[21] Zhang M, Shah AM. ROS signalling between endothelial cells and cardiac 
cells. Cardiovascular research. 2014;102:249-57. 
[22] Leucker TM, Bienengraeber M, Muravyeva M, Baotic I, Weihrauch D, 
Brzezinska AK, et al. Endothelial-cardiomyocyte crosstalk enhances 
pharmacological cardioprotection. Journal of molecular and cellular 
cardiology. 2011;51:803-11. 
[23] Leucker TM, Ge ZD, Procknow J, Liu Y, Shi Y, Bienengraeber M, et al. 
Impairment of endothelial-myocardial interaction increases the susceptibility 
of cardiomyocytes to ischemia/reperfusion injury. PloS one. 2013;8:e70088. 
[24] Bell RM, Mocanu MM, Yellon DM. Retrograde heart perfusion: the 
Langendorff technique of isolated heart perfusion. Journal of molecular and 
cellular cardiology. 2011;50:940-50. 
[25] Vila-Petroff M, Salas MA, Said M, Valverde CA, Sapia L, Portiansky E, et al. 
CaMKII inhibition protects against necrosis and apoptosis in irreversible 
ischemia-reperfusion injury. Cardiovascular research. 2007;73:689-98. 
[26] Hartree EF. Determination of protein: a modification of the Lowry method 
that gives a linear photometric response. Analytical biochemistry. 
1972;48:422-7. 
[27] Chung BH, Kim S, Kim JD, Lee JJ, Baek YY, Jeoung D, et al. Syringaresinol 
causes vasorelaxation by elevating nitric oxide production through the 
phosphorylation and dimerization of endothelial nitric oxide synthase. 
Experimental & molecular medicine. 2012;44:191-201. 
 23 
[28] Hausenloy DJ, Yellon DM, Mani-Babu S, Duchen MR. Preconditioning 
protects by inhibiting the mitochondrial permeability transition. American 
journal of physiology Heart and circulatory physiology. 2004;287:H841-9. 
[29] Vicencio JM, Yellon DM, Sivaraman V, Das D, Boi-Doku C, Arjun S, et al. 
Plasma exosomes protect the myocardium from ischemia-reperfusion 
injury. Journal of the American College of Cardiology. 2015;65:1525-36. 
[30] Davidson SM, Hausenloy D, Duchen MR, Yellon DM. Signalling via the 
reperfusion injury signalling kinase (RISK) pathway links closure of the 
mitochondrial permeability transition pore to cardioprotection. The 
international journal of biochemistry & cell biology. 2006;38:414-9. 
[31] Kelm M. Nitric oxide metabolism and breakdown. Biochimica et biophysica 
acta. 1999;1411:273-89. 
[32] Schmidt TS, Alp NJ. Mechanisms for the role of tetrahydrobiopterin in 
endothelial function and vascular disease. Clinical science. 2007;113:47-63. 
[33] Rafikov R, Fonseca FV, Kumar S, Pardo D, Darragh C, Elms S, et al. eNOS 
activation and NO function: structural motifs responsible for the 
posttranslational control of endothelial nitric oxide synthase activity. The 
Journal of endocrinology. 2011;210:271-84. 
[34] Crompton M. The mitochondrial permeability transition pore and its role in 
cell death. The Biochemical journal. 1999;341 ( Pt 2):233-49. 
[35] Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition 
pore opening during myocardial reperfusion--a target for cardioprotection. 
Cardiovascular research. 2004;61:372-85. 
[36] Ong SB, Samangouei P, Kalkhoran SB, Hausenloy DJ. The mitochondrial 
permeability transition pore and its role in myocardial ischemia reperfusion 
injury. Journal of molecular and cellular cardiology. 2015;78:23-34. 
[37] Lempiainen J, Finckenberg P, Mervaala EE, Storvik M, Kaivola J, Lindstedt 
K, et al. Dexmedetomidine preconditioning ameliorates kidney ischemia-
reperfusion injury. Pharmacology research & perspectives. 2014;2:e00045. 
[38] Jiang L, Li L, Shen J, Qi Z, Guo L. Effect of dexmedetomidine on lung 
ischemiareperfusion injury. Molecular medicine reports. 2014;9:419-26. 
[39] Kucuk A, Yaylak F, Cavunt-Bayraktar A, Tosun M, Arslan M, Comu FM, et al. 
The protective effects of dexmedetomidine on hepatic ischemia reperfusion 
injury. Bratislavske lekarske listy. 2014;115:680-4. 
[40] Yoshitomi O, Cho S, Hara T, Shibata I, Maekawa T, Ureshino H, et al. Direct 
protective effects of dexmedetomidine against myocardial ischemia-
reperfusion injury in anesthetized pigs. Shock. 2012;38:92-7. 
[41] Kocoglu H, Karaaslan K, Gonca E, Bozdogan O, Gulcu N. Preconditionin 
effects of dexmedetomidine on myocardial ischemia/reperfusion injury in 
rats. Current therapeutic research, clinical and experimental. 2008;69:150-
8. 
[42] Si Y, Bao H, Han L, Shi H, Zhang Y, Xu L, et al. Dexmedetomidine protects 
against renal ischemia and reperfusion injury by inhibiting the JAK/STAT 
signaling activation. Journal of translational medicine. 2013;11:141. 
[43] Kim HJ, Sohn JT, Jeong YS, Cho MS, Kim HJ, Chang KC, et al. Direct effect 
of dexmedetomidine on rat isolated aorta involves endothelial nitric oxide 
 24 
synthesis and activation of the lipoxygenase pathway. Clinical and 
experimental pharmacology & physiology. 2009;36:406-12. 
[44] Naaz S, Ozair E. Dexmedetomidine in current anaesthesia practice- a 
review. Journal of clinical and diagnostic research : JCDR. 2014;8:GE01-4. 
[45] Mimuro S, Katoh T, Suzuki A, Yu S, Adachi YU, Uraoka M, et al. 
Deterioration of myocardial injury due to dexmedetomidine administration 
after myocardial ischaemia. Resuscitation. 2010;81:1714-7. 
[46] Schulz R, Kelm M, Heusch G. Nitric oxide in myocardial 
ischemia/reperfusion injury. Cardiovascular research. 2004;61:402-13. 
[47] Phillips L, Toledo AH, Lopez-Neblina F, Anaya-Prado R, Toledo-Pereyra LH. 
Nitric oxide mechanism of protection in ischemia and reperfusion injury. 
Journal of investigative surgery : the official journal of the Academy of 
Surgical Research. 2009;22:46-55. 
[48] Zaman J, Jeddi S, Ghasemi A. The effects of ischemic postconditioning on 
myocardial function and nitric oxide metabolites following ischemia-
reperfusion in hyperthyroid rats. The Korean journal of physiology & 
pharmacology : official journal of the Korean Physiological Society and the 
Korean Society of Pharmacology. 2014;18:481-7. 
[49] Fan Q, Yang XC, Liu Y, Wang LF, Liu SH, Ge YG, et al. Postconditioning 
attenuates myocardial injury by reducing nitro-oxidative stress in vivo in rats 
and in humans. Clinical science. 2011;120:251-61. 
[50] Ferdinandy P, Schulz R. Nitric oxide, superoxide, and peroxynitrite in 
myocardial ischaemia-reperfusion injury and preconditioning. British journal 
of pharmacology. 2003;138:532-43. 
[51] Farah C, Reboul C. NO Better Way to Protect the Heart during Ischemia-
Reperfusion: To be in the Right Place at the Right Time. Frontiers in 
pediatrics. 2015;3:6. 
[52] Burley DS, Ferdinandy P, Baxter GF. Cyclic GMP and protein kinase-G in 
myocardial ischaemia-reperfusion: opportunities and obstacles for survival 
signaling. British journal of pharmacology. 2007;152:855-69. 
[53] Das A, Smolenski A, Lohmann SM, Kukreja RC. Cyclic GMP-dependent 
protein kinase Ialpha attenuates necrosis and apoptosis following 
ischemia/reoxygenation in adult cardiomyocyte. The Journal of biological 
chemistry. 2006;281:38644-52. 
[54] Cohen MV, Yang XM, Liu Y, Solenkova NV, Downey JM. Cardioprotective 
PKG-independent NO signaling at reperfusion. American journal of 
physiology Heart and circulatory physiology. 2010;299:H2028-36. 
[55] Gewaltig MT, Kojda G. Vasoprotection by nitric oxide: mechanisms and 
therapeutic potential. Cardiovascular research. 2002;55:250-60. 
[56] Das A, Xi L, Kukreja RC. Protein kinase G-dependent cardioprotective 
mechanism of phosphodiesterase-5 inhibition involves phosphorylation of 
ERK and GSK3beta. The Journal of biological chemistry. 2008;283:29572-
85. 
[57] Das A, Salloum FN, Xi L, Rao YJ, Kukreja RC. ERK phosphorylation 
mediates sildenafil-induced myocardial protection against ischemia-
 25 
reperfusion injury in mice. American journal of physiology Heart and 
circulatory physiology. 2009;296:H1236-43. 
[58] Ong SB, Dongworth RK, Cabrera-Fuentes HA, Hausenloy DJ. Role of the 
MPTP in conditioning the heart - translatability and mechanism. British 
journal of pharmacology. 2015;172:2074-84. 
[59] Bell RM, Yellon DM. Conditioning the whole heart--not just the 
cardiomyocyte. Journal of molecular and cellular cardiology. 2012;53:24-32. 
 
 26 
 
Figure legends 
 
Fig. 1. Experimental protocols for Langendorff experiments. Isolated rat hearts 
were randomly assigned to the different experimental groups. Control: perfusion 
of Krebs Henseleit buffer for 30 min. Dex: treatment with Dex (10 nM) for 25 min. 
Dex/L-NAME: treatment with L-NAME (100 nM) for 30 min and co-administration 
of Dex (10 nM) for 25 min. Dex/PTIO: treatment with PTIO (100 nM) for 30 min 
and coadministration of Dex (10 nM) for 25 min. Dex/KT5823: Treatment with 
KT5823 (1 µM) for 30 min and co-administration of Dex (10 nM) for 25 min. After 
the treatments, all hearts were subjected to 30 min of global ischemia and 120 
min of reperfusion. White arrows show determination of nitrites, gray arrows 
show evaluation of samples by Western blot and black arrows show the 
assessment of infarct size and LV function. 
 
Fig. 2. Dex promotes eNOS dimerization and nitrite production in ex vivo hearts. 
Isolated adult rat hearts were treated with or without Dex (10 nM) for 25 min. (A) 
Nitrites were assessed by the Griess reaction during perfusion with Krebs 
Henseleit buffer (white circles) or Dex (10 nM) (black circles) at 0, 5, 10 and 20 
min (n: 3-6). (B) Nitrites were also measured at the end of the washout period (n: 
4-6). (C) Western blot of whole heart lysates showing the formation of eNOS 
dimers in response to Dex (10 nM) after the 5 min washout period (upper panel). 
Densitometric quantification of eNOS dimers vs GAPDH (lower panel) (n = 3). 
*P<0.05,**P<0.01 vs Control. Data were analyzed by t test. Bar graphs represent 
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mean ± SEM. 
 
Fig. 3. Dex reduces myocardial infarct size by an eNOS-NO-PKG dependent 
mechanism in isolated adult rat hearts subjected to global IR. Representative 
images of heart slices (upper panel). Mean percentage of the infarct size of 
groups IR, Dex, Dex/L-NAME, Dex/PTIO and Dex/KT5823 after 30 min of global 
ischemia and 120 min of reperfusion. Hearts were stained with TTC 1% at the 
end of reperfusion. Bar graphs represent mean ± SEM. The number of 
experiments is shown for each bar (lower panel). *P<0.05 vs. IR, Dex/L-NAME, 
Dex/PTIO and Dex/KT5823. Data were analyzed by one-way ANOVA, followed 
by Tukey’s post-test. 
 
Fig. 4. Dex improves hemodynamic parameters through an eNOS-NO-PKG 
dependent mechanism in isolated adult rat hearts after global IR. Means of LV 
function recovery: (A) LVDP, (B) LVEDP, (C) +dP/dtmax, and (D) -dP/dtmin of 
groups I/R, Dex, Dex/L-NAME, Dex/PTIO and Dex/KT5823 at baseline conditions 
and at the end of reperfusion (n: 4-5). Bar graphs represent mean ± SEM. 
P<0.05 vs IR, Dex/L-NAME, Dex/PTIO and Dex/KT5823. #P<0.05 vs IR. Data 
were analyzed by two-way ANOVA, followed by Bonferroni’s post-test. 
 
Fig. 5. Dex does not delay mPTP opening or reduce cell death in 
cardiomyocytes. (A) Adult rat cardiomyocytes were incubated with TMRM (3 µM) 
for 20 min and treated with or without Dex (10 nM) for 5 min and the opening of 
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mPTP was assessed by confocal microscopy (n: 3). (B) Representative images 
of adult rat cardiomyocytes treated with or without Dex (10 nM) for 15 min and 
then subjected to 3 h of simulated ischemia and 1 h of reperfusion. Insulin (10 
nM) was used as a positive control (left). Cell death was assessed by quantifying 
the percentage of PI+ cells (right) (n = 3). ##P<0.001 vs normoxia. *P<0.05 vs sIR 
and sIR + Dex. Data were analyzed using one-way ANOVA followed by Tukey’s 
post-test. 
 
Fig.6. Dex requires the endothelium to reduce cardiomyocyte death after sIR. (A) 
Representative images of adult rat cardiomyocytes (ARC) co-cultured for 15 min 
with HUVEC cells (EC) pre-treated with or without Dex 10 nM for 5 min. Co-
cultured transwells were then removed and cardiomyocytes were subjected to 
sIR (upper panel). Quantification of the percentage of PI+ cells (lower panel) (n = 
4 independent experiments). ###P<0.0001 vs. normoxia. *P<0.05 vs. sIR, sIR + 
Co-culture 15 min and sIR + Dex. Data were analyzed by one-way ANOVA 
followed by Tukey’s post-test. 
